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Summary
The hazard ratio is one of the most commonly reported measures of treatment effect
in randomised trials, yet the source of much misinterpretation. This point was made
clear by Hernán (2010) in commentary, which emphasised that the hazard ratio contrasts
populations of treated and untreated individuals who survived a given period of time,
populations that will typically fail to be comparable - even in a randomised trial - as a
result of different pressures or intensities acting on both populations. The commentary
has been very influential, but also a source of surprise and confusion. In this note, we aim
to provide more insight into the subtle interpretation of hazard ratios and differences, by
investigating in particular what can be learned about treatment effect from the hazard ratio
becoming 1 after a certain period of time. Throughout, we will focus on the analysis of
randomised experiments, but our results have immediate implications for the interpretation
of hazard ratios in observational studies.
Keywords: Causality; Cox regression; Hazard ratio; Randomized study; Survival analysis.
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1 Introduction
The popularity of the Cox regression model has contributed to the enormous success of the
hazard ratio as a concise summary of the effect of a randomised treatment on a survival
endpoint. Notwithstanding this, use of the hazard ratio has been criticised over recent
years. Hernán (2010) argued that selection effects render a causal interpretation of the
hazard ratio difficult when treatment affects outcome. While the treated and untreated
people are comparable by design at baseline, the treated people who survive a given time t
may then tend to be more frail (as a result of lower mortality if treatment is beneficial) than
the untreated people who survive the given time t, so that the crucial comparability of both
groups is lost at that time. Aalen et al. (2015) re-iterated Hernán’s concern. They viewed
the problem more as one of non-collapsibility (Martinussen and Vansteelandt, 2013), which
is a concern about the interpretation of the hazard ratio, though not about its justification
as a causal contrast. In particular, they argued that the magnitude of the hazard ratio
typically changes as one evaluates it in smaller subgroups of the population (e.g. frail
people), even in the absence of interaction effects on the log hazard scale. In this paper, we
aim to develop more insight into these matters. We will focus in particular on what can be
learned about the treatment effect from the hazard ratio becoming 1 after a certain point
in time. Throughout, we will assume that data are available from a randomised experiment
on the effect of a dichotomous treatment A (coded 1 for treatment and 0 for control) on
a survival endpoint T , so that issues of confounding can be ignored, although our findings
naturally extend to observational studies.
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2 The Cox model and causal reasoning
Analyses of time-to-event endpoints in randomised experiments are commonly based on
the Cox model
λ(t; a) = λ0(t)e
βa,
where λ(t; a) denotes the hazard function of T given A = a, evaluated at time t, and λ0(t)
is the unspecified baseline hazard function. This model implies that for all t
P (T > t|A = 1) = P (T > t|A = 0)exp(β), (1)
which suggests that the exponential of β can be interpreted as
exp(β) =
logP (T > t|A = 1)
logP (T > t|A = 0) .
This represents a causal contrast (i.e., it compares the same population under different
interventions). Indeed, let T a denote the potential event time we would see if the exposure
A is set to a. Then, since randomisation ensures that T a ⊥⊥ A for a = 0, 1, we have that
exp(β) =
logP (T 1 > t)
logP (T 0 > t)
.
This shows that, under the proportional hazard assumption, exp(β) forms a relative con-
trast of what the log survival probability would be at an arbitrary time t if everyone were
treated, versus what it would be at that time if no one were treated.
The log-transformation makes the above interpretation of exp(β), while causal, diffi-
cult. It is therefore more common to interpret exp(β) as a hazard ratio
exp(β) =
limh→0 P (t ≤ T < t+ h|T ≥ t, A = 1)
limh→0 P (t ≤ T < t+ h|T ≥ t, A = 0) =
limh→0 P (t ≤ T 1 < t+ h|T 1 ≥ t)
limh→0 P (t ≤ T 0 < t+ h|T 0 ≥ t) .
Interpretation appears simpler now, but this is somewhat deceptive for two reasons. First,
the righthand expression shows that exp(β) contrasts the hazard functions with and with-
out intervention for two separate groups of individuals, those who survive time t > 0 with
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treatment (T 1 ≥ t) and those who survive time t > 0 without treatment (T 0 ≥ t). Those
groups will typically fail to be comparable if treatment affects outcome (Hernán, 2010).
In particular, when treatment has a beneficial effect then, despite randomisation, the sub-
group T 1 ≥ t in the numerator will generally contain more frail people than the subgroup
T 0 ≥ t in the denominator, where the frailest people may have died already. When viewed
as a hazard ratio, exp(β) therefore does not represent a causal contrast. Second, the inter-
pretation of exp(β) as a hazard ratio is further complicated by it being non-collapsible, so
that its magnitude typically becomes more pronounced as one evaluates smaller subgroups
of the study population (Martinussen and Vansteelandt, 2013; Aalen et al., 2015).
The summary so far is that, under the assumption of proportional hazards, the pa-
rameter exp(β) in the Cox model expresses a causal effect, namely the ratio of log survival
probabilities with versus without treatment in the study population. Because this interpre-
tation is not insightful, results are best communicated by visualising identity (1) in terms
of estimated survival curves with versus without treatment (Hernán, 2010). This has the
advantage that it provides better insight into the possible public health impact of the in-
tervention, but the drawback that it does not permit a compact way of reporting and that
survival curves do not provide an understanding of a possible dynamic treatment effect.
To enable a more in-depth understanding, it is tempting to interpret exp(β) as a hazard
ratio, but then interpretation becomes subtle. We will demonstrate this in more detail
in the next section, where we will investigate to what extent hazard ratios may provide
insight into the dynamic nature of the treatment effect.
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3 Time-varying hazard ratios are not causally interpretable
Consider now a study where the hazard ratio changes with time in the following sense:
λ(t;A = 1)
λ(t;A = 0)
=
{
exp(β1) if t ≤ ν
exp(β2) if t > ν
(2)
with β1 6= β2, where ν > 0 denotes the change point, which we assume to be known based
on subject matter knowledge. Suppose in particular that β1 < 0 and β2 = 0. This is
commonly interpreted as if treatment is initially beneficial, but becomes ineffective from
time ν onwards. We present a practical example in Section 4.2 where this situation arises.
In the following sections, we will reason whether such interpretation is justified, and thus
whether hazard ratios permit a dynamic understanding of the treatment effect.
3.1 A closer look at the causal mechanism
To develop a greater understanding, we will first develop insight into data-generating pro-
cesses (DGP) that could give rise to (2). Let Z represent the participants’ unmeasured
baseline frailty (higher means more frail), which affects T , but is independent of A by
randomisation. Suppose that the hazard function λ(t; a, z) of T given A = a and Z = z
satisfies
λ(t; a, z) = zλ∗(t; a), (3)
for some function λ∗(t; a), and let Z be Gamma distributed with mean 1 and variance θ.
This specific choice is not essential, however, and we later consider a situation where Z is
binary.
We will investigate what choices of λ∗(t; a) give rise to model (2). With φZ(u) =
E(e−Zu) the Laplace transform associated with the distribution of Z, the following rela-
tionship between the hazard function of interest λ(t;A), and λ∗(t;A), can be shown to
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hold:
Λ∗(t; a) = φ−1Z (e
−Λ(t;a)) =
1− e−θΛ(t;a)
θe−θΛ(t;a)
,
where Λ(t; a) =
∫ t
0
λ(s; a) ds and similarly with Λ∗(t; a). Simple calculations then show
that model (3) implies model (2) when
λ(t;A,Z) =
{
Zλ0(t)e
β1A exp {θΛ0(t)eβ1A} if t ≤ ν
Zλ0(t)e
β2A exp
{
θΛ0(ν)e
β1A + θΛ0(ν, t)e
β2A
}
if t > ν (4)
where Λ0(ν, t) =
∫ t
ν
λ0(s) ds. For subjects with given Z = z, it follows that the conditional
hazard ratio, which we term HRZ(t), is
λ(t;A = 1, Z)
λ(t;A = 0, Z)
=
{
exp(β1) exp [θΛ0(t){exp(β1)− 1}] if t ≤ ν
exp(β2) exp [θΛ0(ν){exp(β1)− 1}+ θΛ0(ν, t){exp(β2)− 1}] if t > ν
For β2 = 0, this simplifies to
λ(t;A = 1, Z)
λ(t;A = 0, Z)
=
{
exp(β1) exp [θΛ0(t){exp(β1)− 1}] if t ≤ ν
exp [θΛ0(ν){exp(β1)− 1}] if t > ν
which is smaller than 1 at all time points when, as previously assumed, β1 < 0. We
conclude that treatment appears beneficial at all times amongst individuals with the same
value z of Z, regardless of z. This contradicts the earlier, naïve interpretation that, across
all individuals combined, treatment is ineffective from time ν onwards.
The root cause of these contradictory conclusions is the fact that the hazard ratio at
a given time does not express a causal effect (Hernán, 2010). This has nothing to do with
model misspecification, as all considered models hold by construction. In particular, when
β2 = 0 and θ = 1, then
E(Z|T > t,A = 1)
E(Z|T > t,A = 0) =
{
exp {Λ0(t)(1− eβ1)} if t ≤ ν
exp {Λ0(ν)}+Λ0(ν,t)
exp {Λ0(ν)eβ1}+Λ0(ν,t) if t > ν.
While Z is independent of A by randomisation, it is thus no longer so amongst subgroups
of survivors, where we are left with more frail subjects in the active treatment group:
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E(Z|T > t,A = 1) > E(Z|T > t,A = 0). That selection takes place does not rely on Z
being Gamma-distributed; see Appendix A.1, where we consider a situation with a binary
frailty variable.
To illustrate further, we generated a single data set with Z binary with P (Z = 0.2) =
0.2 and P (Z = 1.2) = 0.8 corresponding to low and high risk groups. The treatment
variable A was binary with P (A = 1|Z) = 0.5. Further, we took β1 = − log (2), β2 = 0, the
baseline hazard function λ0(t) = 0.4, and the change point ν = 4. We took a large sample
size n = 20000 so that sampling variability is small, and induced censoring according to a
uniform distribution on [0, 10], randomly for half of the individuals, and the rest censored
at t = 8, resulting in an overall censoring percent of approximately 19%. The result from
a change point Cox analysis was βˆ1 = −0.67 (SE 0.018) and βˆ2 = −0.03 (SE 0.034).
The corresponding hazard ratios are 0.51 for t ≤ 4 and 1.03 for t > 4. In contrast, the
conditional hazard ratio in Figure 1 is seen to be smaller than 1 at all times, not only in
the first initial period. Indeed, no matter the value of Z, it lies between 0.33 and 0.80 in
the considered time period from 0 to 8.
That we are misled by the hazard ratios calculated from the extended Cox regression
analysis is due to selection taking place. This is shown in Figure 2, where we have plotted
E(Z|T > t,A = a) for a = 0, 1. Since the treatment has a beneficial effect, we are left with
more and more frail subjects in this group compared to the untreated group. In Figure 2,
the blue curve (A = 1) therefore lies consistently above the green curve (A = 0).
As just shown, the DGP given by λ(t;A,Z) with ν = ∞ implies the marginal Cox
model. It is tempting to interpret HRZ(t) as a causal hazard ratio, but this only holds
under further untestable assumptions as shown in Section 3.2 and 3.4. In Appendix A.2,
we formulate a more general DGP so that both the marginal Cox model and the model
λ(t;A,Z) are correctly specified.
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3.2 Towards a causal hazard ratio
To remedy this problem, it seems intuitively of interest to evaluate conditional hazard
ratios
limh→0 P (t ≤ T < t+ h|T ≥ t, A = 1, Z = z)
limh→0 P (t ≤ T < t+ h|T ≥ t, A = 0, Z = z) =
limh→0 P (t ≤ T 1 < t+ h|T 1 ≥ t, Z = z)
limh→0 P (t ≤ T 0 < t+ h|T 0 ≥ t, Z = z) ,
for a large collection of baseline variables Z, such that those who survive time t > 0 with
treatment (T 1 ≥ t) are comparable to those who survive time t > 0 without treatment
(T 0 ≥ t), but have the same covariate values z. Such comparability would be attained if
T 1 ⊥⊥ T 0|Z. (5)
Under this assumption, it follows via Bayes’ rule that the righthand side of the above
identity equals
limh→0 P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t, Z = z)
limh→0 P (t ≤ T 0 < t+ h|T 0 ≥ t, T 1 ≥ t, Z = z) . (6)
This estimand expresses the instantaneous risk at time t on treatment versus control for
the principal stratum of individuals with covariates z who would have survived up to time
t, no matter what treatment. It represents a causal contrast, which is closely related to the
so-called survivor average causal effect (Rubin, 2000). We will refer to it as the conditional
causal hazard ratio.
Unfortunately, the assumption (5) is untestable and biologically implausible, as it is
essentially impossible to believe that one can get hold of all predictors of the event time
such that knowledge of the event time without treatment does not further predict the event
time with treatment. Furthermore, even if one could get hold of all such predictors, then
because Z would probably carry so much information about the event time, one would
logically expect the numerator and denominator of (6) to be so close to 0 or 1 that it
would render the conditional causal hazard ratio essentially meaningless. Below, we will
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therefore focus on the marginal causal hazard ratio HR(t) obtained from (6) with Z empty:
HR(t) =
limh→0 P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t)
limh→0 P (t ≤ T 0 < t+ h|T 0 ≥ t, T 1 ≥ t) . (7)
3.3 Why causal hazard ratios are not identified without strong
assumptions
The reason why the causal hazard ratio (7) is not identifiable without invoking strong as-
sumptions is that it attempts to answer an overly ambitious question. Imagine a trial that
randomises participants over an implanted medical device (e.g. a stent or a pacemaker)
versus no treatment (or placebo). Suppose that the medical device gradually deteriorates
and stops being operational after some time ν. Then we would say that treatment no
longer works from time ν onwards. This would correspond with HR(t) = 1 for t ≥ ν. How-
ever, how could data from a randomised trial be informative about the effect of treatment
after time ν when no information is collected on the times at which the medical device is
operational or not? To learn about the treatment effect at each time t, we should ideally
need data At on whether (At = 1) or not (At = 0) the device is operational at that time.
When the operation time is ignorable, then one may learn about the treatment effect at
each time t through contrasts of the form
limh→0 P (s ≤ T < s+ h|T ≥ s, At− = 1, At = 1)
limh→0 P (s ≤ T < s+ h|T ≥ s, At− = 1, At = 0)
,
for all s ≥ t, where At− is the information generated by all Au, u < t. It is unsurprising that
without detailed data on the operation times of each device, strong assumptions are needed
to develop insight into the dynamic nature of the treatment effect. Likewise, consider a trial
that randomises participants over a once-daily treatment regimen versus placebo. Then
we would say that treatment no longer works from time ν onwards when, from that time
onwards, patients with the same history of treatment experience the same outcomes (in
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distribution), whether or not they continue treatment. To infer when treatment becomes
ineffective, a multi-stage design is ideally needed where patients on the treatment arm
may randomly be switched to the control arm at designated points in time. Without such
design, some progress can still be made with data on daily pill intake. However, without
such design and data, inferring when treatment becomes ineffective remains an ambitious
undertaking.
3.4 Sensitivity analysis
Some further insight into the magnitude of the causal hazard ratio at a given time t can
be obtained under the monotonicity assumption that no one is harmed by treatment, i.e.
T 1 ≥ T 0 with probability 1.
Under this assumption, we can write
P (t ≤ T < t+h|T ≥ t, A = 0) = P (t ≤ T 0 < t+h|T 0 ≥ t) = P (t ≤ T 0 < t+h|T 0 ≥ t, T 1 ≥ t)
and
P (t ≤ T < t+ h|T ≥ t, A = 1) = P (t ≤ T 1 < t+ h|T 1 ≥ t)
= P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t)pi(t)
+P (t ≤ T 1 < t+ h|T 0 < t, T 1 ≥ t) {1− pi(t)} ,
with
pi(t) ≡ P (T 0 ≥ t|T 1 ≥ t) = P (T
0 ≥ t)
P (T 1 ≥ t) =
P (T ≥ t|A = 0)
P (T ≥ t|A = 1) .
It follows that
λ(t;A = 1)
λ(t;A = 0)
= HR(t) [pi(t) + SR(t) {1− pi(t)}] , (8)
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where
SR(t) ≡ limh→0 P (t ≤ T
1 < t+ h|T 0 < t, T 1 ≥ t)
limh→0 P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t) .
compares the instantaneous risk at time t on treatment for individuals who remained event-
free at time t thanks to treatment versus individuals who would have been event-free at time
t regardless of treatment. It can be viewed as a selection effect and is therefore termed a
sensitivity ratio (SR). Expression (8) thus conveys that the dependence of the hazard ratio
λ(t;A = 1)/λ(t;A = 0) on time t may differ from the causal hazard ratio on time as a result
of selection effects. In particular, when the observed hazard ratio λ(t;A = 1)/λ(t;A = 0) is
constant, e.g. suggesting a beneficial treatment effect of 0.8, then this will often correspond
with a more pronounced treatment effect HR(t) ≤ 0.8. This results from (8), if SR(t) ≥ 1,
as 0 ≤ pi(t) ≤ 1. The causal hazard ratio HR(t) then need not be constant. This may be
the result of varying treatment effectiveness over time, but may also be the result of the
patient population (the principal stratum T 0 ≥ t, T 1 ≥ t) changing with time. It follows
from the above results that
HR(t) =
λ(t;A = 1)
λ(t;A = 0)
[pi(t) + SR(t) {1− pi(t)}]−1 .
All terms in the righthand side, apart from SR(t), are identified from the observed data.
The above expression may therefore be used as the basis of a sensitivity analysis where
the user tries different choices of SR(t). However, it is not clear what would be reasonable
values of SR(t), and the monotonicity assumption may also not be plausible.
Assume instead that there is a Z so that (5) holds, and so that the DGP is governed
by
λ(t;A,Z) = exp {ψ0(t, A) + ψ1(t, Z)} (9)
for some general functions ψ0 and ψ1, then
HR(t) =
E{P (T 1 = t|T 1 ≥ t, Z)|T 0 ≥ t, T 1 ≥ t}
E{P (T 0 = t|T 0 ≥ t, Z)|T 0 ≥ t, T 1 ≥ t} = exp {ψ0(t, 1)− ψ0(t, 0)} = HRZ(t)
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Thus, if (5) and (9) hold then HR(t) = HRZ(t). In the worked application in Section 4.1
we compare HR(t) to the Cox hazard ratio while modelling the correlation between T 0 and
T 1 letting Z be Gamma distributed with varying variance so that (5) and (9) hold. As a
further illustration we now describe how to simulate data so that (5) and (9) are fulfilled,
and so that the marginal Cox model, conditioning only on A, is also correctly specified.
Take A, Z, V0 and V1 to be independent so that Z is Gamma distributed with mean 1 and
variance θ, V0 and V1 are exponentially distributed with mean 1, and the exposure A is
binary with P (A = 1) = 1/2. Then let T 0 = 1
θ
log ( θ
Z
V0 + 1), T
1 = 1
θeβ
log ( θ
Z
V1 + 1), and
let T = (1−A)T 0 +AT 1. It follows directly that (5) holds, and further that the marginal
Cox model is correctly specified, and also that
λ(t;A,Z) = Z exp {βA+ θeβAt}
so (9) also holds. Thus, HR(t) = HRZ(t), and
HR(t) = eβ exp {tθ(eβ − 1)}.
Different values of θ will give different values of Kendall’s τ corresponding to different
correlation between T 0 and T 1. In the specific setting, we have τ = θ/(θ + 2). Figure 3
displays HR(t) in scenarios with different values of Kendall’s τ . Note that the marginal
Cox model induces the hazard ratio eβ, which is taken to be eβ = 0.5. It is seen that
HR(t) is equal to eβ only under independence between T 0 and T 1; otherwise HR(t) looks
like a decreasing function in t with HR(0) = eβ. When T 0 and T 1 are highly correlated
(Kendall’s τ = 0.93) then HR(t) is sharply decreasing towards zero. In Appendix A.4
we describe another DGP where again (5) holds and the marginal Cox model is correctly
specified, but HR(t) and HRZ(t) are different due to failure of (9).
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3.5 Hazard differences
Under some conditions, hazard differences - as opposed to hazard ratios - have a more ap-
pealing interpretation, apart from them being collapsible (Martinussen and Vansteelandt,
2013). In particular, suppose that the additive hazards model
λ(t;A,Z) = ψ(t)A+ ω(t, Z), (10)
holds for general functions ψ, ω and baseline covariates Z. It has been shown that under
this model, the baseline exchangeability of treated and untreated individuals w.r.t. the
covariates Z, as guaranteed by randomisation, implies that A ⊥⊥ Z|T > t (Vansteelandt
et al., 2014; Aalen et al., 2015). However, since this is equivalent to
P (Z = z |T 0 > t) = P (Z = z |T 1 > t), (11)
it does not mean that there is a balance in the risk set, because (11) shows that this is
a comparison between two different groups of people: those with T 0 > t and those with
T 1 > t. Indeed, the hazard difference
ψ(t) = lim
h→0
P (t ≤ T 1 < t+ h|T 1 ≥ t)− lim
h→0
P (t ≤ T 0 < t+ h|T 0 ≥ t)
may not represent a causal contrast. If (5) holds, e.g. that Z is a sufficiently rich collection
of variables that includes T 0 and T 1 (or deterministically predicts T 0 and T 1) then the
above hazard difference reduces to
ψ(t) = lim
h→0
P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t)− lim
h→0
P (t ≤ T 0 < t+ h|T 0 ≥ t, T 1 ≥ t),
which represents a causal contrast. This is shown in Appendix A.5. While it is implau-
sible to have such rich collection of data that it essentially deterministically predicts T 0,
interestingly, when model (10) holds for Z including T 0, then it can be fitted without data
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on T 0. Indeed, by collapsibility of the hazard difference (Martinussen and Vansteelandt,
2013), the hazard difference ψ(t) can be consistently estimated via Aalen least squares
estimation in the unadjusted model
λ(t;A) = ψ(t)A.
Unfortunately, however, the additive structure of model (10) will often be unlikely satisfied
w.r.t. a rich collection of variables that predict T 0, and thus the practical implications of
the above reasoning remain limited. For instance, in the simulation study of Section 3.1,
the marginal Aalen additive hazards model fits the data perfectly, because A is binary, but
also suggests a beneficial effect of the treatment in the first 4 years, which then disappears,
see Figure 4.
4 Applications
4.1 MRC RE01 study
As an illustration, we reconsider the kidney cancer data described in White and Roys-
ton (2009). These data are from the MRC RE01 study that was a randomised controlled
trial comparing interferon-α (IFN) treatment with the best supportive care and hormone
treatment with medroxyprogesterone acetate (control) in patients with metastatic renal
carcinoma. We use the same 347 patients as in White and Royston (2009). In this illustra-
tive analysis we consider only the first 30 months of follow up. The median follow-up time
was 242 days, and 85% of the patients died within the considered time frame. The two
Kaplan-Meier estimates in Figure 5 contain all the available information about the treat-
ment effect. IFN treatment seems superior to the standard treatment (control), although
a supremum test comparing the two survival curves results in a non-significant p-value
of 0.09. The score process plot of Lin et al. (1993) was calculated using the R-package
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timereg (Martinussen and Scheike, 2006), giving no evidence against the proportional
hazards assumption (P 0.43 according to the supremum test). We therefore fitted the Cox
model, giving the estimate βˆ = −0.29 (SE 0.12, P 0.01), showing evidence that the IFN
treatment reduces the risk of dying for these patients. The hazard ratio of 0.75 expresses
the magnitude of the causal effect, but interpretation is subtle as explained before. As
a sensitivity analysis we now assume (5) and (9), and take Z to be Gamma distributed
with mean 1 and variance θ. This model fits the observed data equally well and thus
cannot be refuted based on the observed data. The parameter θ expresses the correlation
between T 0 and T 1 and was chosen to give a Kendall’s τ of 0.1 and 0.2 corresponding
to estimated Kendall’s τ concerning the correlation between lifetimes for dizygotic and
monozygotic Danish twins (Scheike et al., 2015). A higher correlation between T 0 and T 1,
corresponding to a Kendall’s τ of 0.3, was also considered. Figure 6 displays HR(t) under
these three scenarios. It is seen that HR(t) is smaller than 0.75 at all times and decreases
with time indicating a stronger treatment effect when comparing the instantaneous risk at
time t on treatment versus control for the principal stratum of individuals who would have
survived up to time t, no matter what treatment. This is more pronounced with the larger
correlation. In view of these subtleties of interpretation, in this section, we will focus on a
number alternative ways of describing the treatment effect.
We may alternatively use the Cox model to estimate the relative risk function
RR(t) =
P (T ≤ t|A = 1)
P (T ≤ t|A = 0) =
P (T 1 ≤ t)
P (T 0 ≤ t) ,
which can be estimated consistently by
R̂R(t) =
1− exp {−Λˆ0(t)eβˆ}
1− exp {−Λˆ0(t)}
,
where βˆ is the Cox partial likelihood estimator and Λˆ0(t) is the corresponding Breslow
estimator. This estimate, along with 95% pointwise and uniform confidence bands, is
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displayed in Figure 7, where we see that the estimated relative risk function is below 1 at
all times, in favour of the IFN treatment. For instance, it is seen that the relative risk
at one year is estimated to be approximately 0.85, and, judging from the 95% confidence
bands (dashed curves), this is close to being significant. A uniform test over the considered
time span is also close to being significant judging from the 95% uniform confidence bands.
Another way of quantifying the treatment effect is by using the restricted mean survival
time (RMST) (Uno et al., 2014; Zhao et al., 2016). The RMST up to time t is defined
as RMST(t) = E{min(T, t)}. This is the area under the survival curve of T up to time
t and can easily be estimated using the corresponding Kaplan-Meier curve up to time t
(see Zhao et al. (2016) for details on inference). Contrasts of the RMST(t) corresponding
to different (randomised) treatment groups therefore carry a causal interpretation. The
restricted mean time lost, RMTL(t) is defined as t − RMST(t). Here, the ‘months of life
lost up to 30 months’ is given by RMTL(30) and estimated to 17.3 for the IFN treatment
and to 19.8 for the control treatment. The ratio of these two (IFN vs control) is 0.87 (95%
CI, 0.70 to 1.04). Thus, on IFN treatment there is a 13% less loss of lifetime compared to
the control treatment during the first 30 months of follow up.
We also fitted Aalen’s additive hazard model
λ(t;A, V ) = β0(t) + ψ(t)A+ β1(t)
TV, (12)
where V includes days from metastasis to randomization (log-transformed), WHO perfor-
mance status (0, 1 and 2; with group 0 and 1 collapsed into one group), and Haemoglobin
(g/dl). As the treatment variable A is independent of the other covariates, the above Aalen
model is collapsible meaning that the interpretation of ψ(t) is the same in the conditional
and marginal model. The Cox model does not have this property. Model (12) appeared
to fit the data well, using the tools described in Chapter 5 in Martinussen and Scheike
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(2006); specifically no interaction between the treatment indicator and the baseline risk
factors was found. We estimated Ψˆ(t) =
∫ t
0
ψ(s)ds both from the conditional model and
the marginal model, and the two estimators were almost identical, which, as pointed out,
should be the case if model (12) is correctly specified. Using model (12), we next tested the
null hypothesis ψ(t) = ψ of a constant effect (P 0.58), which was subsequently estimated to
be ψˆ = −0.02 (SE, 0.009). If T 0 ⊥⊥ T 1|V (or if the addition of additional variables Z con-
ditional on which T 0 and T 1 become independent, does not change the additive structure
of the model), then this is also the causal hazard difference. This would mean that over
the course of the follow-up, an average of approximately 2 additional deaths will occur for
each month of follow-up in each 100 persons under the control treatment alive at the start
of the month and who would also be alive under the IFN treatment, compared with each
100 IFN treated persons alive at the start of the month and who would also be alive under
the control treatment. As suggested before, the assumption that T 0 ⊥⊥ T 1|V is implausible
however.
4.2 Gastrointestinal tumour study
Stablein and Koutrouvelis (1985) presented survival data from a randomized clinical trial on
locally unresectable gastric cancer. Half of the total 90 patients were assigned to chemother-
apy, and the other half to combined chemotherapy and radiotherapy. It was suggested that
there was superior survival for patients who received chemotherapy, but only in the first
year or so. The same application was considered by Collett (2015) p. 386-389. For illustra-
tive purposes we consider here the first 720 days of follow up corresponding to the two first
time periods considered by Collett (2015). Figure 8 displays the Kaplan Meier curves cor-
responding to the two groups, and shows that the survival curves become close at the end
of the considered time interval. Applying a Cox regression model with time-by-treatment-
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interaction, allowing for separate HR’s before and after 1 year of follow-up gives estimated
HR’s (Combined vs chemotherapy) of 2.40 (95% CI; 1.25, 4.63) in the first year and 0.78
(95% CI; 0.34,1.76) thereafter (the supremum score process test of Lin et al. (1993) gave no
convincing evidence against these two models, with P 0.07 in the first interval and P 0.26
in the second interval). Thus one might be tempted to conclude that the chemotherapy is
beneficial in the first year only, and that there might even be a reverse effect afterwards,
see Collett (2015) for a similar analysis and conclusion. However, arguing based on the
two hazard ratios is subtle as we have shown. If chemotherapy is more effective then there
will be more and more frail subjects in that group making the interpretation of hazard
function difficult. We illustrate this using the two estimated hazard ratios and taking the
frailty variable to be Gamma distributed mean and variance equal to θ corresponding to a
Kendall’s τ of 0.3. Figure 9 displays the estimated λ(t, A = 1, Z)/λ(t, A = 0, Z) which is
seen to depend on time, being larger than 2.4 and increasing towards 3.7 in the first year
and, after the change-point (1 year), starting at around 1.2 and then decreasing but being
larger than 1 at all times.
5 Concluding Remarks
We have argued that the treatment effect in a proportional hazards model carries a causal
interpretation, but that its interpretation is subtle. The proportional hazards assumption
does not express, for instance, that treatment works equally effectively at all times, as the
hazard ratio at a given time mixes differences between treatment arms due to treatment
effect as well as selection. The danger of over interpreting hazard ratios become most
pronounced when the hazard ratio is not constant over time (e.g. when the hazard ratio
is below 1 for some time and then becomes 1). We have argued that this cannot be
interpreted as implying that treatment effectiveness disappears after some time. In our
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opinion, this is the source of much confusion, and a real concern. Non-constant hazard
ratios are indeed fairly common in real life because the proportional hazards assumption is
a rather unstable assumption in the following sense. Even when valid in some population,
this assumption is likely to fail in subgroups of that population (e.g. if one studies men and
women separately), and vice versa. This makes the assumption, at best, an approximation
in practice.
We have suggested possibilities to estimate hazard ratios that are causally interpretable
because they compare intensities at a given time t with and without treatment for the
same patient population: those who would survive that time, no matter what treatment.
Inferring such hazard ratios necessitates a sensitivity analysis, however. Furthermore, they
have the disadvantage of describing the effect for an unknown subgroup of the population.
A better strategy in practice, when interest lies in the dynamic aspects of a treatment, is
therefore to design the study such that the collected data provide immediate insight into
the dynamic aspects of treatment (e.g. by modifying treatment assignments over time).
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Appendix A
A.1 Binary frailty variable
Let Z be binary, for instance P (Z = 0.2) = 0.2 and P (Z = 1.2) = 0.8, low and high risk
groups, then E(Z) = 1, and similar results as in the Gamma-distribution case (Section
3.1) are obtained. In this binary case, the Laplace transform is
φZ(u) = 0.2e
−0.2u + 0.8e−1.2u.
Therefore
HRZ(t)
gZ(e
−Λ(t,a=1))
gZ(e−Λ(t,a=0))
=
λ(t; a = 1)
λ(t; a = 0)
,
where
gZ(u) = {D log (φZ)}{φ−1Z (u)}, (13)
which is an increasing function. Hence, if we take β1 < 0 and β2 = 0, then again
HRZ(t) < 1
for all t.
A.2 Frailty model arising by marginalization
It was shown in Section 3.1 that one can always pick a DGP λ(t;A,Z) so that the Cox
model holds marginally, only conditioning on the observed A. Rename Z to Z1. We
show now that similarly we can also pick a DGP λ(t;A,Z1, Z2) so that it marginalizes to
λ(t;A,Z1) that further marginalizes to λ(t;A), the latter being the Cox model. For ease
of calculations, let
λ(t;A,Z1, Z2) = Z2λ
∗(t;A,Z1)
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with Z2 being Gamma distributed with mean and variance equal to 1, and independent of
Z1 and A. Similar calculations as those in Section 3.1 gives the following expression
λ(t;A,Z1, Z2) = Z1Z2λ0(t)e
βA exp
[
Λ0(t)e
βA + Z1{exp {Λ0(t)eβA − 1}
]
(14)
Hence, if the DGP is governed by (14) then model (4), with ν =∞, and the marginal Cox
model, only conditioning on A, are also correctly specified.
A.3 Selection and Cox model
Assume that the Cox model λ(t;A) is correctly specified. Will there always be selection?
The answer is yes. The Cox model induces randomness as
Λ0(T ) = e
−AβV,
where V is exponentially distributed with mean 1. But then
E(V |T > t,A = a) = E(V |V > eaβΛ0(t), A = a) = 1 + eaβΛ0(t).
If eβ < 1 then
E(V |T > t,A = 1) < E(V |T > t,A = 0).
A.4 A DGP with HR(t) and HRZ(t) being different
Let Z be Gamma distributed with mean 1− α, α ∈ (0, 1), and variance 1, and let V0 and
V1 be independent Gamma distributed with mean α and variance 1. Exposure A is binary
with P (A = 1) = 1/2. Generate data as follows: T 0 = V0 + Z, T 1 = e−β(V1 + Z) and
T = (1− A)T 0 + AT 1. Condition (5) holds, and the marginal Cox model is also correctly
specified. But in this case HR(t) 6= HRZ(t), and it also easily seen that HRZ(t) depends
on Z. Different values of α results in different values of Kendall’s τ thus controlling the
correlation between T 0 and T 1.
22
A.5 Hazard differences
We assume (5) and (10). Then
lim
h→0
P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t) = ψ(t) + E{ω(t, Z)e
−2 ∫ t0 ω(s,Z) ds}
E{e−2
∫ t
0 ω(s,Z) ds}
and
lim
h→0
P (t ≤ T 0 < t+ h|T 0 ≥ t, T 1 ≥ t) = E{ω(t, Z)e
−2 ∫ t0 ω(s,Z) ds}
E{e−2
∫ t
0 ω(s,Z) ds}
and therefore
ψ(t) = lim
h→0
P (t ≤ T 1 < t+ h|T 0 ≥ t, T 1 ≥ t)− lim
h→0
P (t ≤ T 0 < t+ h|T 0 ≥ t, T 1 ≥ t).
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Figure 1: Simulation study. Plot of HRZ(t).
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Figure 2: Simulation study. Plot of E(Z|T > t,A = a), a = 0, 1.
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Figure 3: HR(t) in scenarios with eβ = 0.5 and with Kendall’s τ equal to 0, 0.04, 0.2, 0.49, 0.83
and 0.98 (starting from top with τ equal to 0, corresponding to independence between T 0 and
T 1).
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Figure 4: Simulation study. Estimated cumulated regression coefficient and 95% pointwise
confidence bands obtained from fitting the Aalen additive hazards model.
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Figure 5: MRC RE01 study. Kaplan Meier plot, control group (green curve) and IFN group
(blue curve).
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Figure 6: MRC RE01 study. Estimated HR(t) with Kendall’s τ equal to 0.3 (dotted curve), 0.2
(broken curve) and 0.1 (full curve). Horizontal line corresponds to the Cox hazard ratio of 0.74.
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Figure 7: MRC RE01 study. IFN treatment vs control treatment. Estimate of relative risk RR(t)
along with 95% pointwise confidence bands (dashed curves) and 95% uniform bands (shaded area).
27
0 200 400 600 800 1000
0.0
0.2
0.4
0.6
0.8
1.0
Time (days)
Figure 8: Gastrointestinal tumour study. Kaplan-Meier plot, chemotherapy (full curve) and
combined therapy (broken curve).
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Figure 9: Gastrointestinal tumour study. Plot of λ(t;A = 1, Z)/λ(t;A = 0, Z) based on (4) with
change-point at 1 year and the frailty variable being Gamma distributed with mean 1 and variance
so that Kendall’s τ is equal to 0.3. Dashed curves show the estimated regression coefficients based
on the change-point Cox analysis. Combined therapy vs chemotherapy.
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